WCBA
EW icon

Weaver C. Barksdale & Associates’s Edwards Lifesciences EW Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-83,307
Closed -$2.45M – 530
2016
Q1 		$2.45M Buy
+83,307
New +$2.3M 1.84% 24

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Weaver C. Barksdale & Associates's EW Position: Q2 2016 in Review

Weaver C. Barksdale & Associates sold out of Edwards Lifesciences (EW) in Q2 2016, closing a stake of 83,307 shares — an estimated $2.45M sold.

Weaver C. Barksdale & Associates first reported a position in EW in Q1 2016 and held it in 1 quarter. The position peaked at $2.45M in Q1 2016. 692 funds tracked by Wall St. Rank hold EW as of Q2 2016.

  • Weaver C. Barksdale & Associates reported no remaining Edwards Lifesciences position as of Q2 2016 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 83,307 Edwards Lifesciences shares in Q2 2016, an estimated $2.45M.
  • Weaver C. Barksdale & Associates first reported a position in Edwards Lifesciences in Q1 2016 and held it in 1 quarter.
  • Weaver C. Barksdale & Associates's Edwards Lifesciences position peaked at $2.45M in Q1 2016.
  • 692 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2016.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2016, filed 11 Jul 2016.